Norcross, Georgia-based Galectin Therapeutics Inc.'s shares finished Friday's session 9.57% higher at $1.03 with a total trading volume of 365,355 shares. The stock has surged 63.49% in the last one month. The Company's shares are trading above their 50-day moving average by 17.85%. Moreover, shares of Galectin Therapeutics, which engages in the research and development of therapies for fibrotic disease and cancer, have a Relative Strength Index (RSI) of 63.98. Visit us today and download your complete report on GALT for free at:
Shares in Cambridge, Massachusetts headquartered Momenta Pharmaceuticals Inc. ended the day 2.76% higher at $14.90 with a total trading volume of 403,336 shares. The stock has advanced 18.25% in the last one month, 25.53% over the previous three months, and 0.40% on an YTD basis. The Company's shares are trading 18.15% above their 50-day moving average and 33.73% above their 200-day moving average. Moreover, shares of Momenta Pharma, which focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases, have an RSI of 63.06.
On November 22nd, 2016, research firm Aegis Capital initiated a 'Hold' rating on the Company's stock. The complimentary research report on MNTA can be accessed at:
Newton, Massachusetts headquartered Karyopharm Therapeutics Inc.'s stock rose 0.33%, closing the session at $9.21. A total volume of 150,787 shares was traded. The Company's shares have gained 2.68% in the previous three months. The stock is trading 3.11% and 9.39% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Karyopharm Therapeutics, which focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases, have an RSI of 50.63. Register for free on Stock-Callers.com and download the PDF research report on KPTI at:
On Friday, shares in Woodcliff Lake, New Jersey headquartered Eagle Pharmaceuticals Inc. finished the session 0.94% lower at $75.85 with a total trading volume of 220,483 shares. The stock has gained 21.54% over the previous three months. The Company's shares are trading above their 50-day and 200-day moving averages by 6.32% and 38.66%, respectively. Furthermore, shares of Eagle Pharma, which focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the US, have an RSI of 50.59.
On November 16th, 2016, research firm Mizuho downgraded the Company's stock rating from 'Buy' to 'Neutral', issuing a target price of $78 per share. Get free access to your research report on EGRX at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA